Alzheimer's disease is responsible for 60%-70% of dementia cases (AD). The need for effective medicines to treat Alzheimer's disease has grown urgent, as the number of patients with the disease continues to rise. Although much is known about Alzheimer's disease, there is still an unknown underlying cause. This makes it more difficult to identify medicines that can stop it in its tracks. Current Alzheimer's disease treatments, such as cholinesterase inhibitors and an N-methyl-D-aspartate receptor antagonist may temporarily relieve dementia symptoms but do not stop or reverse disease development. However, researchers have developed new generation pharmacological treatments that would slow down the cortical breakdown mechanism.
Journal of Immunology and Immunotherapy received 6 citations as per Google Scholar report